PARP-1 expression as a prognostic factor in Desmoid-type fibromatosis

Bräutigam, Konstantin; Lindner, Judith; Budczies, Jan; Pahl, Stefan; Kunitz, Annegret; Melcher, I.; Wust, Peter; Nebrig, Maxim; Baur, Alexander; Denkert, Carsten; Pfitzner, Berit Maria

doi:10.1016/j.anndiagpath.2019.151442

Cited by 7 publications

(7 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with positive expression of Ki-67 and a high signal on T2-weighted MRI have a higher probability of recurrence after surgery (19). In addition, higher PARP-1 (a DNA repairing enzyme) expression is also associated with earlier recurrence of DTs (20). In 2013, Crago et al constructed a nomogram, which included age, location and tumor diameter based on these recurrence factors, that can roughly predict the probability of recurrence in DT patients.…”

Section: Introductionmentioning

confidence: 99%

Development, Validation, and Visualization of A Web-Based Nomogram for Predicting the Recurrence-Free Survival Rate of Patients With Desmoid Tumors

Liu

Huang

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

BackgroundSurgery is an important treatment option for desmoid tumor (DT) patients, but how to decrease and predict the high recurrence rate remains a major challenge.MethodsDesmoid tumor patients diagnosed and treated at Tianjin Cancer Institute & Hospital were included, and a web-based nomogram was constructed by screening the recurrence-related risk factors using Cox regression analysis. External validation was conducted with data from the Fudan University Shanghai Cancer Center.ResultsA total of 385 patients were identified. Finally, after excluding patients without surgery, patients who were lost to follow-up, and patients without complete resection, a total of 267 patients were included in the nomogram construction. Among these patients, 53 experienced recurrence, with a recurrence rate of 20.15%. The 3-year and 5-year recurrence-free survival (RFS) rates were 82.5% and 78%, respectively. Age, tumor diameter, admission status, location, and tumor number were correlated with recurrence in univariate Cox analysis. In multivariate Cox analysis, only age, tumor diameter and tumor number were independent risk factors for recurrence and were then used to construct a web-based nomogram to predict recurrence. The concordance index (C-index) of the nomogram was 0.718, and the areas under the curves (AUCs) of the 3-year and 5-year receiver operating characteristic (ROC) curves were 0.751 and 0.761, respectively. In the external validation set, the C-index was 0.706, and the AUCs of the 3-year and 5-year ROC curves are 0.788 and 0.794, respectively.ConclusionsAge, tumor diameter, and tumor number were independent predictors of recurrence for DTs, and a web-based nomogram containing these three predictors could accurately predict RFS (https://stepforward.shinyapps.io/Desmoidtumor/).

show abstract

Section: Introductionmentioning

confidence: 99%

Development, Validation, and Visualization of A Web-Based Nomogram for Predicting the Recurrence-Free Survival Rate of Patients With Desmoid Tumors

Liu

Huang

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Currently, PARP inhibitors are used in specific types of cancers such as breast, ovarian, pancreatic, and metastatic castration-resistant prostate cancer and potentially DF. Of note, hormone receptors were of minor prognostic relevance in this study showing a significant difference with other types of tumors such as breast cancer [24].…”

Section: Parp-1mentioning

confidence: 62%

Desmoid-type Fibromatosis of the Breast. A Literature Review Based on 2 Case Reports

2024

J Oncol Res Ther

View full text Add to dashboard Cite

The goal of this review is twofold; to highlight the difficulties in identifying, diagnosing, and treating desmoid-type fibromatosis (DF) of the breast and to discuss the current understanding of the key genetic mutations in the disease process that lead to specific treatment regimens. Currently, there are three groups of DF as classified by the World Health Organization (WHO): abdominal wall, extra-abdominal, and intrabdominal. They all present unique diagnostic challenges; however, the gold standard for diagnosis remains histopathologic confirmation even with the increased availability and sensitivity of imaging modalities. Given the importance of genetic alteration in this disease, the following three genes will be discussed: Catenin Beta 1, Rad51, and Poly Adenosine Diphosphate Ribose Polymerase-1. There is mounting evidence that these could potentially be targets for therapy in addition to surgery alone. Historically, diagnosis and treatment of DF of the breast have been difficult, which leads to a need for an interdisciplinary team approach composed of surgeons, pathologists, radiologists, oncologists, and internists which leads to the best overall care for patients with this pathology.

show abstract

“…Six studies evaluated the role of sex steroids in desmoid tumour pathogenesis [ 36 , 42 , 43 , 45 – 47 ]. Oestrogen receptor-β (ERβ) expression was demonstrated in all studies and ranged from 7.4% to 90% [ 36 , 42 , 43 , 45 – 47 ], whilst only Ishizuka et al demonstrated oestrogen receptor-α (ERα) expression in two patients [ 46 ]. ERβ significantly correlated with the expression of cyclin A ( r = 0.34, p = 0.004), cyclin D1 ( r = 0.34, p = 0.004) and Ki-67 ( r = 0.35, p = 0.003) [ 36 ].…”

Section: Resultsmentioning

confidence: 99%

“…ERβ significantly correlated with the expression of cyclin A ( r = 0.34, p = 0.004), cyclin D1 ( r = 0.34, p = 0.004) and Ki-67 ( r = 0.35, p = 0.003) [ 36 ]. Ishizuka et al also demonstrated positive progesterone receptor A and B expression in 25.9% and 33.3% of DTF cases respectively [ 46 ], whilst the remaining studies were negative for progesterone receptor expression [ 42 , 43 , 47 ]. In addition to sex steroid receptor analysis, Brautigam et al found poly(ADP-ribose) polymerase 1 (PARP1) expression in 98.3% of DTF cases, which negatively correlated with Ki-67 expression (Spearman–Rho test, − 0.375, p = 0.041) [ 47 ].…”

Section: Resultsmentioning

confidence: 99%

Molecular Pathogenesis of Sporadic Desmoid Tumours and Its Implications for Novel Therapies: A Systematised Narrative Review

2022

View full text Add to dashboard Cite

Sporadic desmoid-type fibromatosis is a rare, fibroblastic soft-tissue neoplasm with local aggressiveness but no metastatic potential. Aberrant Wnt/β-catenin signalling has been extensively linked to desmoid pathogenesis, although little is known about other molecular drivers and no established treatment approach exists. We aimed to summarise the current literature regarding the molecular pathogenesis of sporadic desmoid-type fibromatosis and to discuss the effects of both current and emerging novel therapies targeting these mechanisms. A literature search was conducted of MEDLINE ® ALL and EMBASE databases for published studies (2000–August 2021) using keywords related to ‘fibromatosis aggressive’, ‘immunohistochemistry’, ‘polymerase chain reaction’ and ‘mutation’. Articles were included if they examined the role of proteins in sporadic or extra-abdominal human desmoid-type fibromatosis pathogenesis. Searching identified 1684 articles. Following duplicate removal and eligibility screening, 36 were identified. After a full-text screen, 22 were included in the final review. At least 47% of desmoid-type fibromatosis cases displayed aberrant β-catenin immunoreactivity amongst ten studies. Cyclin D1 overexpression occurred in at least 40% of cases across five studies. Six studies reported oestrogen receptor-β expression with a range of 7.4–90%. Three studies implicated matrix metalloproteinases, with one study demonstrating vascular endothelial growth factor overexpression. One study explored the positive relationship between cyclooxygenase-2 and platelet-derived growth factor receptor-β. Aberrant Wnt/β-catenin signalling is a well-established pathogenic driver that may be targeted via downstream modulation. Growth factor signalling is best appreciated through the clinical trial effects of multi-targeted tyrosine kinase inhibitors, whilst oestrogen receptor expression data may only offer a superficial insight into oestrogen signalling. Finally, the tumour microenvironment presents multiple potential novel therapeutic targets.

show abstract

PARP-1 expression as a prognostic factor in Desmoid-type fibromatosis

Cited by 7 publications

References 20 publications

Development, Validation, and Visualization of A Web-Based Nomogram for Predicting the Recurrence-Free Survival Rate of Patients With Desmoid Tumors

Development, Validation, and Visualization of A Web-Based Nomogram for Predicting the Recurrence-Free Survival Rate of Patients With Desmoid Tumors

Desmoid-type Fibromatosis of the Breast. A Literature Review Based on 2 Case Reports

Molecular Pathogenesis of Sporadic Desmoid Tumours and Its Implications for Novel Therapies: A Systematised Narrative Review

Contact Info

Product

Resources

About